Trial reportJournal of translational medicine2018
Nonclinical and clinical pharmacological characterization of the potent and selective cathepsin K inhibitor MIV-711.
Trial report in Journal of translational medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 41 citations in OpenAlex.
- Therapeutic subtypes of knee osteoarthritis: differential treatment effects among predicted endotypes in past clinical trials.Arthritis research & therapy · 2026Article
- Bone adhesive with temporally-synchronized degradation for enhanced osteointegration.Bone research · 2026Article
- Relationship between cathepsin K and extracellular matrix dynamics: a comprehensive review.Frontiers in oncology · 2026Review
- Structural and Proteomic Analysis of the Mouse Cathepsin B-DARPin 4m3 Complex Reveals Species-Specific Binding Determinants.International journal of molecular sciences · 2025Article
- Cathepsin K Inhibitors as Potential Drugs for the Treatment of Osteoarthritis.International journal of molecular sciences · 2025Review
- Antibody-peptide conjugates deliver covalent inhibitors blocking oncogenic cathepsins.Nature chemical biology · 2024Article
- Animal Models of Osteoarthritis: Updated Models and Outcome Measures 2016-2023.Regenerative engineering and translational medicine · 2024Article
- Ultrasound-Responsive Nanobubbles for Combined siRNA-Cerium Oxide Nanoparticle Delivery to Bone Cells.Pharmaceutics · 2023Article
- Latest insights in disease-modifying osteoarthritis drugs development.Therapeutic advances in musculoskeletal disease · 2023Review
- Cathepsin K in Pathological Conditions and New Therapeutic and Diagnostic Perspectives.International journal of molecular sciences · 2022Review
- Identifying small molecules for protecting chondrocyte function and matrix integrity after controlled compressive injury.Osteoarthritis and cartilage open · 2022Article
- Therapeutic Treatments for Osteoporosis-Which Combination of Pills Is the Best among the Bad?International journal of molecular sciences · 2022Review
- The current state of the osteoarthritis drug development pipeline: a comprehensive narrative review of the present challenges and future opportunities.Therapeutic advances in musculoskeletal disease · 2022Review
- Dual Targeting Anti-Osteoporotic Therapy Through Potential Nanotherapeutic Approaches.Pharmaceutical nanotechnology · 2022Review
- New developments in osteoarthritis pharmacological therapies.Rheumatology (Oxford, England) · 2021Review
- Challenges and opportunities of pharmacological interventions for osteoarthritis: A review of current clinical trials and developments.Osteoarthritis and cartilage open · 2021Review
- Disease-modifying therapeutic strategies in osteoarthritis: current status and future directions.Experimental & molecular medicine · 2021Review
- Prospects for Therapies in Osteoarthritis.Calcified tissue international · 2021Review
- 3D assessment of intervertebral disc degeneration in zebrafish identifies changes in bone density that prime disc disease.Bone research · 2021Article
- Regulatory properties of vitronectin and its glycosylation in collagen fibril formation and collagen-degrading enzyme cathepsin K activity.Scientific reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCathepsin K is an attractive therapeutic target for diseases in which bone resorption is excessive such as osteoporosis and osteoarthritis (OA). The current paper characterized the pharmacological profile of the potent and selective cathepsin K inhibitor, MIV-711, in vitro and in cynomolgus monkeys, and assessed translation to human based on a single dose clinical study in man.
methodsThe potency and selectivity of MIV-711 were assessed in vitro using recombinant enzyme assays and differentiated human osteoclasts. MIV-711 was administered to healthy cynomolgus monkeys (3-30 µmol/kg, p.o.). Plasma levels of MIV-711 and the bone resorption biomarker CTX-I were measured after single dose experiments, and urine levels of CTX-I, NTX-I and CTX-II biomarkers were measured after repeat dose experiments. The safety, pharmacokinetics and pharmacodynamics (serum CTX-I) of MIV-711 were assessed in human healthy subjects after single ascending doses from 20 to 600 mg.
resultsMIV-711 was a potent inhibitor of human cathepsin K (K
conclusionsMIV-711 is a potent and selective cathepsin K inhibitor with dose-dependent effects on biomarkers of bone and cartilage degradation in monkey and human. Taken together, MIV-711 shows promise for the treatment of bone and cartilage related disorders in humans, such as OA. Trial Registration EudraCT number 2011-003024-12, registered on June 22nd 2011.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.